<?xml version="1.0" encoding="UTF-8"?>
<p>At the data cut‐off (18 October 2016), 60 patients (94%) had discontinued study treatment: 20 (31%) to undergo ASCT; 13 (20%) due to an AE; 13 (20%) due to progressive disease; 4 (6%) due to withdrawal of consent; 1 (2%) due to unsatisfactory therapeutic response; and 9 (14%) for other reasons (patient [
 <italic>n </italic>=
 <italic> </italic>4] or investigator [
 <italic>n </italic>=
 <italic> </italic>2] decision to discontinue treatment but continue follow‐up, health complications unrelated to study drug, patient removed, lost to follow‐up [each 
 <italic>n </italic>=
 <italic> </italic>1]). Four patients (6%) remained on study treatment (phase 1, 
 <italic>n </italic>=
 <italic> </italic>1; phase 2, 
 <italic>n </italic>=
 <italic> </italic>3).
</p>
